NASDAQ:ETNB 89bio Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.47 -0.15 (-4.14%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$3.31▼$3.8450-Day Range$2.09▼$3.9552-Week Range$2.00▼$22.31Volume1.26 million shsAverage Volume235,072 shsMarket Capitalization$70.62 millionP/E RatioN/ADividend YieldN/APrice Target$41.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ETNB Stock Forecast (MarketRank)Overall MarketRank™2.25 out of 5 starsMedical Sector339th out of 1,411 stocksPharmaceutical Preparations Industry144th out of 672 stocksAnalyst Opinion: 3.6Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 3.6 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.88, 89bio has a forecasted upside of 905.0% from its current price of $3.47.Amount of Analyst Coverage89bio has only been the subject of 2 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform Votes89bio has received 72 “outperform” votes. (Add your “outperform” vote.)Underperform Votes89bio has received 33 “underperform” votes. (Add your “underperform” vote.)Community Sentiment89bio has received 68.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about 89bio and other stocks. Vote “Outperform” if you believe ETNB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ETNB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have not sold or bought any company stock.Percentage Held by Insiders11.80% of the stock of 89bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.06% of the stock of 89bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($4.41) to ($4.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 89bio (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock News HeadlinesJune 21, 2022 | benzinga.com89bio To Present Additional Pegozafermin Data At EASL International Liver Congress 2022 - Benzinga - BenzingaJune 21, 2022 | globenewswire.com89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022 - GlobeNewswireJune 21, 2022 | finance.yahoo.com89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022June 21, 2022 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Given Consensus Recommendation of "Buy" by BrokeragesJune 10, 2022 | benzinga.com89bio Pulls Back With Market — But Could The Stock Soar 250%? - Benzinga - BenzingaJune 10, 2022 | americanbankingnews.comCantor Fitzgerald Weighs in on 89bio, Inc.'s FY2023 Earnings (NASDAQ:ETNB)May 13, 2022 | benzinga.comAnalyst Ratings for 89bio - Benzinga - BenzingaMay 13, 2022 | seekingalpha.comETNB stock gains on Raymond James upgrade (NASDAQ:ETNB) - Seeking AlphaMay 13, 2022 | finance.yahoo.com89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update - Yahoo FinanceMay 12, 2022 | benzinga.comBenzinga's Top Ratings Upgrades, Downgrades For May 12, 2022 - Benzinga - BenzingaMay 12, 2022 | streetinsider.comForm 8-K 89bio, Inc. For: May 11 - StreetInsider.comMay 12, 2022 | marketwatch.com89bio Shares Rise 19% After Narrower-Than-Expected 1Q Loss - MarketWatchMay 12, 2022 | benzinga.comRaymond James Upgrades 89bio to Strong Buy, Lowers Price Target to $12 - Benzinga - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-500-4614FaxN/AEmployees41Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today6/26/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$34.88 High Stock Price Forecast$60.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+1,093.9%Consensus RatingBuy Rating Score (0-4)3.14285714285714 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.63% Return on Assets-62.29% Debt Debt-to-Equity Ratio0.14 Current Ratio7.36 Quick Ratio7.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.21 per share Price / Book0.56Miscellaneous Outstanding Shares20,351,000Free Float17,950,000Market Cap$70.62 million OptionableNot Optionable Beta2.72 89bio Frequently Asked Questions Should I buy or sell 89bio stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 89bio stock. View analyst ratings for 89bio or view top-rated stocks. What is 89bio's stock price forecast for 2022? 7 brokers have issued 1 year target prices for 89bio's stock. Their ETNB stock forecasts range from $12.00 to $60.00. On average, they expect 89bio's share price to reach $34.88 in the next twelve months. This suggests a possible upside of 905.0% from the stock's current price. View analysts' price targets for 89bio or view top-rated stocks among Wall Street analysts. How has 89bio's stock price performed in 2022? 89bio's stock was trading at $13.07 at the beginning of 2022. Since then, ETNB shares have decreased by 73.5% and is now trading at $3.47. View the best growth stocks for 2022 here. When is 89bio's next earnings date? 89bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for 89bio. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) released its quarterly earnings results on Wednesday, May, 11th. The company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.38) by $0.12. View 89bio's earnings history. Who are 89bio's key executives? 89bio's management team includes the following people: Mr. Rohan Palekar, CEO & Director (Age 56, Pay $829.41k) (LinkedIn Profile)Mr. Quoc Le-Nguyen, Chief Technical Operations Officer & Head of Quality (Age 54, Pay $571.12k)Dr. Harry Mansbach M.D., Chief Medical Officer (Age 57, Pay $603.22k)Mr. Ryan Stephen Martins, Chief Financial Officer (Age 44)Mr. Ram Waisbourd, COO & Chief Bus. Officer (Age 55) (LinkedIn Profile)Mr. Shiva K. Natarajan, Sr. VP of Fin. & Principal Accounting Officer (Age 56)Ms. Melissa Abel, Sr. VP of Commercial Strategy & CommunicationsMs. Amanda Hill, VP of People & CultureMs. Yun Bai, VP & Head of CMCMr. Paul Shin, Sr. VP of R&D Operations Who are some of 89bio's key competitors? Some companies that are related to 89bio include Thorne HealthTech (THRN), PepGen (PEPG), Provention Bio (PRVB), LianBio (LIAN), Verona Pharma (VRNA), AC Immune (ACIU), Inventiva (IVA), Alpine Immune Sciences (ALPN), Prelude Therapeutics (PRLD), InterCure (INCR), Rallybio (RLYB), Aadi Bioscience (AADI), KalVista Pharmaceuticals (KALV), Zomedica (ZOM) and Sernova (SEOVF). View all of ETNB's competitors. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), (HON), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? (ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. What is 89bio's stock symbol? 89bio trades on the NASDAQ under the ticker symbol "ETNB." Who are 89bio's major shareholders? 89bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.76%), BlackRock Inc. (4.53%), Bank of America Corp DE (2.06%), Vanguard Group Inc. (1.99%), Pekin Hardy Strauss Inc. (1.77%) and Renaissance Technologies LLC (1.29%). Company insiders that own 89bio stock include Gregory Grunberg, Longitude Capital Partners Iii, Ollin B Sykes, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends for 89bio. Which major investors are selling 89bio stock? ETNB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Vanguard Group Inc., Charles Schwab Investment Management Inc., and Northern Trust Corp. Company insiders that have sold 89bio company stock in the last two years include Gregory Grunberg, Orbimed Advisors Llc, Ram Waisbourd, and Ryan Martins. View insider buying and selling activity for 89bio or view top insider-selling stocks. Which major investors are buying 89bio stock? ETNB stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Renaissance Technologies LLC, Pekin Hardy Strauss Inc., BlackRock Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., GSA Capital Partners LLP, and XTX Topco Ltd. Company insiders that have bought 89bio stock in the last two years include Longitude Capital Partners Iii, Ollin B Sykes, Ra Capital Management, LP, and Rohan Palekar. View insider buying and selling activity for 89bio or or view top insider-buying stocks. How do I buy shares of 89bio? Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 89bio's stock price today? One share of ETNB stock can currently be purchased for approximately $3.47. How much money does 89bio make? 89bio (NASDAQ:ETNB) has a market capitalization of $70.62 million. The company earns $-90.12 million in net income (profit) each year or ($5.00) on an earnings per share basis. How many employees does 89bio have? 89bio employs 41 workers across the globe. How can I contact 89bio? 89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for 89bio is www.89bio.com. The company can be reached via phone at 415-500-4614 or via email at [email protected]. This page (NASDAQ:ETNB) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here